German court suspends mRNA patent trial against BioNTech

CureVac NV

28/09/2023 09:16

DUESSELDORF, Sept 28 (Reuters) - A German court on
Thursday suspended a patent trial against BioNTech  22UAy.DE 
over the use of mRNA technology in the COVID-19 vaccine
developed by the German company together with its U.S. partner
Pfizer.
    The Duesseldorf regional court said it needed further
clarification and suspended the case, brought by BioNTech
competitor CureVac  5CV.DE , pending a decision by the federal
patent court on a lawsuit filed by BioNTech.
    It had asked the higher court to review the validity of
CureVac's intellectual property rights. A decision is expected
in December.

 (Reporting by Tom Kaeckenhoff, Writing by Rachel More, Editing
by Friederike Heine)
 ((rachel.more@thomsonreuters.com;))